Adage Capital Partners Gp, L.L.C. Terns Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 850,000 shares of TERN stock, worth $5.11 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
850,000
Previous 1,050,000
19.05%
Holding current value
$5.11 Million
Previous $6.81 Million
18.17%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding TERN
# of Institutions
118Shares Held
61MCall Options Held
155KPut Options Held
48.3K-
Orbimed Advisors LLC San Diego, CA7.62MShares$45.8 Million1.13% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.66MShares$40 Million5.84% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$36.7 Million1.32% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.43MShares$20.6 Million0.01% of portfolio
-
Vr Adviser, LLC New York, NY3.41MShares$20.5 Million1.92% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $226M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...